Reading the tape
NASDAQ: VERU
Veru Inc.
Healthcare · Biotechnology
Market Cap
$35.47M
52w High
$7.40
52w Low
$2.06
P/E
-2.35
Volume
65.47K
Outstanding Shares
16.05M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -56.67%Revenue (TTM): -98.32%FCF (TTM): 8.38%
What changed
The stock fell 56.67% over the last year. Revenue declined 98.32% over the trailing twelve months. Operating margin moved from -266.39% to -8,065.09%. Free cash flow grew 8.38% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -8,065.09%. Revenue declined 98.32% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.
CEOMitchell S. Steiner
SectorHealthcare
IndustryBiotechnology
Employees210
IPO dateFeb 11, 1999
Valuation
Forward P/E—
EV/EBITDA-1.21
Enterprise value$42.98M
Stock splits
Aug 11, 2025↓ Reverse
Every 10 shares became 1
Profitability & growth
Revenue growth—
Gross margin-46.72%
Operating margin-8,065.09%
ROE-123.97%▼5.98%vs FY2024
Analyst consensus
RatingBuy
Target price$4.00▲81.00%
5
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.29 · Revenue est $1.9M
View